CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021

The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the U...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Neuro-oncology (Charlottesville, Va.) Ročník 26; číslo Supplement_6; s. vi1
Hlavní autoři:	Price, Mackenzie, Ballard, Christine, Benedetti, Julia, Neff, Corey, Cioffi, Gino, Waite, Kristin A, Kruchko, Carol, Barnholtz-Sloan, Jill S, Ostrom, Quinn T
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 06.10.2024
Témata:	Adolescent Adult Aged Aged, 80 and over Brain Neoplasms - epidemiology Brain Neoplasms - pathology Central Nervous System Neoplasms - epidemiology Central Nervous System Neoplasms - pathology Child Child, Preschool Female Follow-Up Studies Humans Incidence Infant Infant, Newborn Male Middle Aged Prognosis Registries - statistics & numerical data Survival Rate United States - epidemiology Young Adult United States
ISSN:	1523-5866, 1523-5866
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. Between 2017 and 2021, the average annual age-adjusted incidence rate (AAAIR) of all primary malignant and non-malignant brain and other CNS tumors was 25.34 per 100,000 population (malignant AAAIR=6.89 and non-malignant AAAIR=18.46). This overall rate was higher in females compared to males (28.77 versus 21.78 per 100,000) and non-Hispanic Black persons compared to persons who were non-Hispanic White (26.60 versus 25.72 per 100,000), non-Hispanic American Indian/Alaska Native (23.48 per 100,000), non-Hispanic Asian or Pacific Islander (19.86 per 100,000), and Hispanic persons of all races (22.37 per 100,000). Gliomas accounted for 22.9% of all tumors. The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (13.9% of all tumors and 51.5% of all malignant tumors), and the most common predominantly non-malignant histopathology was meningioma (41.7% of all tumors and 56.8% of all non-malignant tumors). Glioblastomas were more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.02 per 100,000 population. There were 87,053 deaths attributed to malignant brain and other CNS tumors between 2017 and 2021. This represents an average annual mortality rate of 4.41 per 100,000 population and an average of 17,411 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain or other CNS tumor was 35.7%. For a non-malignant brain or other CNS tumor the five-year relative survival rate was 92.0%.
AbstractList	The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. Between 2017 and 2021, the average annual age-adjusted incidence rate (AAAIR) of all primary malignant and non-malignant brain and other CNS tumors was 25.34 per 100,000 population (malignant AAAIR=6.89 and non-malignant AAAIR=18.46). This overall rate was higher in females compared to males (28.77 versus 21.78 per 100,000) and non-Hispanic Black persons compared to persons who were non-Hispanic White (26.60 versus 25.72 per 100,000), non-Hispanic American Indian/Alaska Native (23.48 per 100,000), non-Hispanic Asian or Pacific Islander (19.86 per 100,000), and Hispanic persons of all races (22.37 per 100,000). Gliomas accounted for 22.9% of all tumors. The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (13.9% of all tumors and 51.5% of all malignant tumors), and the most common predominantly non-malignant histopathology was meningioma (41.7% of all tumors and 56.8% of all non-malignant tumors). Glioblastomas were more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.02 per 100,000 population. There were 87,053 deaths attributed to malignant brain and other CNS tumors between 2017 and 2021. This represents an average annual mortality rate of 4.41 per 100,000 population and an average of 17,411 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain or other CNS tumor was 35.7%. For a non-malignant brain or other CNS tumor the five-year relative survival rate was 92.0%.The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. Between 2017 and 2021, the average annual age-adjusted incidence rate (AAAIR) of all primary malignant and non-malignant brain and other CNS tumors was 25.34 per 100,000 population (malignant AAAIR=6.89 and non-malignant AAAIR=18.46). This overall rate was higher in females compared to males (28.77 versus 21.78 per 100,000) and non-Hispanic Black persons compared to persons who were non-Hispanic White (26.60 versus 25.72 per 100,000), non-Hispanic American Indian/Alaska Native (23.48 per 100,000), non-Hispanic Asian or Pacific Islander (19.86 per 100,000), and Hispanic persons of all races (22.37 per 100,000). Gliomas accounted for 22.9% of all tumors. The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (13.9% of all tumors and 51.5% of all malignant tumors), and the most common predominantly non-malignant histopathology was meningioma (41.7% of all tumors and 56.8% of all non-malignant tumors). Glioblastomas were more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.02 per 100,000 population. There were 87,053 deaths attributed to malignant brain and other CNS tumors between 2017 and 2021. This represents an average annual mortality rate of 4.41 per 100,000 population and an average of 17,411 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain or other CNS tumor was 35.7%. For a non-malignant brain or other CNS tumor the five-year relative survival rate was 92.0%. The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. Between 2017 and 2021, the average annual age-adjusted incidence rate (AAAIR) of all primary malignant and non-malignant brain and other CNS tumors was 25.34 per 100,000 population (malignant AAAIR=6.89 and non-malignant AAAIR=18.46). This overall rate was higher in females compared to males (28.77 versus 21.78 per 100,000) and non-Hispanic Black persons compared to persons who were non-Hispanic White (26.60 versus 25.72 per 100,000), non-Hispanic American Indian/Alaska Native (23.48 per 100,000), non-Hispanic Asian or Pacific Islander (19.86 per 100,000), and Hispanic persons of all races (22.37 per 100,000). Gliomas accounted for 22.9% of all tumors. The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (13.9% of all tumors and 51.5% of all malignant tumors), and the most common predominantly non-malignant histopathology was meningioma (41.7% of all tumors and 56.8% of all non-malignant tumors). Glioblastomas were more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.02 per 100,000 population. There were 87,053 deaths attributed to malignant brain and other CNS tumors between 2017 and 2021. This represents an average annual mortality rate of 4.41 per 100,000 population and an average of 17,411 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain or other CNS tumor was 35.7%. For a non-malignant brain or other CNS tumor the five-year relative survival rate was 92.0%.
Author	Ostrom, Quinn T Benedetti, Julia Ballard, Christine Waite, Kristin A Kruchko, Carol Neff, Corey Price, Mackenzie Barnholtz-Sloan, Jill S Cioffi, Gino
Author_xml	– sequence: 1 givenname: Mackenzie surname: Price fullname: Price, Mackenzie organization: Central Brain Tumor Registry of the United States, Hinsdale, IL, U.S.A – sequence: 2 givenname: Christine surname: Ballard fullname: Ballard, Christine organization: Central Brain Tumor Registry of the United States, Hinsdale, IL, U.S.A – sequence: 3 givenname: Julia surname: Benedetti fullname: Benedetti, Julia organization: Central Brain Tumor Registry of the United States, Hinsdale, IL, U.S.A – sequence: 4 givenname: Corey surname: Neff fullname: Neff, Corey organization: Central Brain Tumor Registry of the United States, Hinsdale, IL, U.S.A – sequence: 5 givenname: Gino surname: Cioffi fullname: Cioffi, Gino organization: Central Brain Tumor Registry of the United States, Hinsdale, IL, U.S.A – sequence: 6 givenname: Kristin A surname: Waite fullname: Waite, Kristin A organization: Central Brain Tumor Registry of the United States, Hinsdale, IL, U.S.A – sequence: 7 givenname: Carol surname: Kruchko fullname: Kruchko, Carol organization: Central Brain Tumor Registry of the United States, Hinsdale, IL, U.S.A – sequence: 8 givenname: Jill S surname: Barnholtz-Sloan fullname: Barnholtz-Sloan, Jill S organization: Center for Biomedical Informatics & Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A – sequence: 9 givenname: Quinn T surname: Ostrom fullname: Ostrom, Quinn T organization: Duke Cancer Institute, Duke University Medical Center, Durham, NC, U.S.A
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/39371035$$D View this record in MEDLINE/PubMed
BookMark	eNpNkEtPwzAQhC1URB9w5Yh85BJqx3GccKPhKVUUtek5cpwNBDVOsR2kSvx4XLVInGZ39e3uaMZooDsNCF1SckNJyqYa-k6rqe4k0IifoBHlIQt4EseDf_UQja39JCSkPKZnaMhSJihhfIR-slm-XK_wyknXWNcoucFL2HbG3eI307TS7PDMyEZjqSu8cB9gcAbaGc-9gvnueotXO-ugxXnfdsbi-0a-685Chf2S5_FaN853-w9g98OQUBGE3sw5Oq3lxsLFUScof3zIs-dgvnh6ye7mgYoYd0FKai7StBZMxFWY1jRWktcCYsF5mZSlbwkoWQIvGa9VWklFSCkirzVRSThB14ezW9N99WBd0TZWwWYjNXj_BaOUiSgJmfDo1RHtyxaqYnuIoPgLLPwFr-5wRQ
CitedBy_id	crossref_primary_10_3389_fmed_2025_1629621 crossref_primary_10_3389_fonc_2025_1657867 crossref_primary_10_1016_j_bioelechem_2025_109036 crossref_primary_10_1016_j_fmre_2024_12_022 crossref_primary_10_1016_j_ctro_2025_100989 crossref_primary_10_1093_neuonc_noaf094 crossref_primary_10_1007_s11060_025_05103_z crossref_primary_10_17116_neiro20258903183 crossref_primary_10_1093_neuonc_noaf001 crossref_primary_10_1016_j_ijbiomac_2025_141998 crossref_primary_10_3390_cimb47080667 crossref_primary_10_1007_s11060_025_05168_w crossref_primary_10_3390_antiox14030351 crossref_primary_10_1053_j_sult_2025_03_001 crossref_primary_10_1016_j_ejso_2025_110223 crossref_primary_10_1007_s10143_025_03719_3 crossref_primary_10_1038_s41598_025_04636_7 crossref_primary_10_1186_s12905_025_03815_y crossref_primary_10_1093_neuonc_noaf142 crossref_primary_10_3390_ph18071057 crossref_primary_10_3389_fonc_2025_1585592 crossref_primary_10_3390_cells14060407 crossref_primary_10_1038_s41417_025_00914_8 crossref_primary_10_1093_neuonc_noaf134 crossref_primary_10_2478_raon_2025_0031 crossref_primary_10_1097_MD_0000000000042862 crossref_primary_10_3390_ijms26115276 crossref_primary_10_1111_bpa_13324 crossref_primary_10_26599_NR_2025_94907338 crossref_primary_10_7759_cureus_81231 crossref_primary_10_1002_brb3_70762 crossref_primary_10_1097_WCO_0000000000001419 crossref_primary_10_1038_s41598_025_00113_3 crossref_primary_10_1002_1878_0261_70102 crossref_primary_10_3390_ijms26020443 crossref_primary_10_3389_fneur_2025_1574614 crossref_primary_10_1016_j_spen_2025_101186 crossref_primary_10_1186_s40537_025_01221_7 crossref_primary_10_1093_noajnl_vdaf038 crossref_primary_10_3390_diagnostics15070896 crossref_primary_10_1016_j_acra_2025_06_047 crossref_primary_10_1016_j_spen_2025_101187 crossref_primary_10_1038_s41420_025_02632_4 crossref_primary_10_1016_j_yao_2025_01_004 crossref_primary_10_1038_s41591_025_03745_0 crossref_primary_10_25259_SNI_947_2024 crossref_primary_10_1007_s40618_025_02674_6 crossref_primary_10_1016_j_endinu_2025_501610 crossref_primary_10_1007_s11060_025_05231_6 crossref_primary_10_1016_j_phymed_2025_156850 crossref_primary_10_1016_j_semdp_2025_150899 crossref_primary_10_1016_j_mtnano_2025_100676 crossref_primary_10_1016_j_cancergen_2025_05_001 crossref_primary_10_1016_j_molmed_2025_01_014 crossref_primary_10_1007_s00210_025_03955_w crossref_primary_10_1007_s11060_025_05179_7 crossref_primary_10_1002_cncr_70026 crossref_primary_10_1007_s11060_024_04929_3 crossref_primary_10_1007_s11060_025_05137_3 crossref_primary_10_24060_2076_3093_2025_15_3_299_307 crossref_primary_10_1007_s11910_025_01440_8 crossref_primary_10_1007_s10014_025_00516_0 crossref_primary_10_1007_s00330_025_11704_z crossref_primary_10_1007_s13691_025_00797_4 crossref_primary_10_1186_s12935_025_03868_x crossref_primary_10_1080_17435889_2025_2563499 crossref_primary_10_1002_btm2_70069 crossref_primary_10_3390_cancers17132151 crossref_primary_10_1007_s10143_025_03725_5 crossref_primary_10_3390_brainsci15030325 crossref_primary_10_1016_j_critrevonc_2025_104647 crossref_primary_10_1093_neuonc_noaf168 crossref_primary_10_7759_cureus_88975 crossref_primary_10_1016_j_lfs_2025_123822 crossref_primary_10_1016_j_biopha_2025_118099 crossref_primary_10_1097_JS9_0000000000002488 crossref_primary_10_12998_wjcc_v13_i25_108429 crossref_primary_10_3390_nano15171338 crossref_primary_10_3390_ijms26167990 crossref_primary_10_1007_s10143_025_03789_3 crossref_primary_10_1093_noajnl_vdaf129 crossref_primary_10_1038_s41392_025_02279_8 crossref_primary_10_3389_fonc_2025_1577816 crossref_primary_10_3390_cancers17183077 crossref_primary_10_2967_jnumed_125_269633 crossref_primary_10_3389_fimmu_2025_1661327 crossref_primary_10_1016_j_isci_2025_113346 crossref_primary_10_1016_j_immuni_2025_04_017 crossref_primary_10_1007_s00401_025_02917_z crossref_primary_10_3390_curroncol32050281 crossref_primary_10_1093_noajnl_vdaf111 crossref_primary_10_3390_ph18060910 crossref_primary_10_1186_s40364_025_00788_w crossref_primary_10_1371_journal_pone_0323461 crossref_primary_10_1016_j_endien_2025_501610 crossref_primary_10_17116_neiro202589041106 crossref_primary_10_3389_fcacs_2025_1572317 crossref_primary_10_1001_jamaneurol_2025_3011 crossref_primary_10_1007_s10544_025_00759_w crossref_primary_10_3389_fimmu_2025_1615359 crossref_primary_10_1515_med_2025_1194 crossref_primary_10_1093_neuonc_noaf158 crossref_primary_10_1007_s11604_025_01821_6 crossref_primary_10_1016_j_celrep_2025_115584 crossref_primary_10_3390_biomedicines13030659 crossref_primary_10_3390_ijms26167803 crossref_primary_10_1007_s12010_025_05362_6 crossref_primary_10_3390_cancers17010121 crossref_primary_10_3389_fnmol_2025_1662414 crossref_primary_10_1016_j_ijpharm_2025_126093 crossref_primary_10_3389_fneur_2025_1568898
ContentType	Journal Article
Copyright	The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Copyright_xml	– notice: The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/neuonc/noae145
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1523-5866
ExternalDocumentID	39371035
Genre	Journal Article
GeographicLocations	United States
GeographicLocations_xml	– name: United States
GrantInformation_xml	– fundername: CDC HHS grantid: 75D30123P17556 – fundername: Musella Foundation For Brain Tumor Research and Information – fundername: National Brain Tumor Society – fundername: American Brain Tumor Association – fundername: NCI NIH HHS
GroupedDBID	--- .2P .I3 .XZ .ZR 0R~ 123 18M 36B 4.4 48X 53G 5WD 70D AABZA AACZT AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNHQ ABNKS ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AGINJ AGKEF AGQXC AGSYK AGUTN AHGBF AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX AOIJS APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DILTD DU5 D~K E3Z EBS ECM EE~ EIF ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HW0 HZ~ IOX J21 JXSIZ KOP KQ8 KSI KSN MHKGH N9A NGC NOMLY NOYVH NPM O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM Q1. Q5Y RD5 ROX RPM RUSNO RW1 RXO TEORI TJX TR2 WOQ X7H YAYTL YKOAZ YXANX ~91 7X8
ID	FETCH-LOGICAL-c435t-90f5799f7376d29f16ca5f7e6755b8bb6ca0ecabe5b35fc9dac00b74dacf0c82
IEDL.DBID	7X8
ISICitedReferencesCount	47
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001326925700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1523-5866
IngestDate	Sun Sep 28 00:33:41 EDT 2025 Wed Oct 08 04:10:31 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	Supplement_6
Language	English
License	The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c435t-90f5799f7376d29f16ca5f7e6755b8bb6ca0ecabe5b35fc9dac00b74dacf0c82
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://academic.oup.com/neuro-oncology/article-pdf/26/Supplement_6/vi1/59464369/noae145.pdf
PMID	39371035
PQID	3113748237
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_3113748237 pubmed_primary_39371035
PublicationCentury	2000
PublicationDate	2024-10-06
PublicationDateYYYYMMDD	2024-10-06
PublicationDate_xml	– month: 10 year: 2024 text: 2024-10-06 day: 06
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Neuro-oncology (Charlottesville, Va.)
PublicationTitleAlternate	Neuro Oncol
PublicationYear	2024
SSID	ssj0021561
Score	2.6959984
Snippet	The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	vi1
SubjectTerms	Adolescent Adult Aged Aged, 80 and over Brain Neoplasms - epidemiology Brain Neoplasms - pathology Central Nervous System Neoplasms - epidemiology Central Nervous System Neoplasms - pathology Child Child, Preschool Female Follow-Up Studies Humans Incidence Infant Infant, Newborn Male Middle Aged Prognosis Registries - statistics & numerical data Survival Rate United States - epidemiology Young Adult
Title	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021
URI	https://www.ncbi.nlm.nih.gov/pubmed/39371035 https://www.proquest.com/docview/3113748237
Volume	26
WOSCitedRecordID	wos001326925700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1FeMhKr1cSO45gF0ULFQEsFRepW-ZWNpLSUiR_POU7LhITEkiiRLcXny913vtN3CF2BUwJQrDnJTORIokRKZJo4IjVTmkpfeVHt9KPo97PRSA7qA7dZXVa5sImVobal8WfkLRbHnimFMnEzeSe-a5TPrtYtNFZRgwGU8VotRsssAnizmi-VMsKzNF2SNrJW4eZlYVpFqVyc8N_hZeVmutv__cAdtFUDTHwbNGIXrbhiD2306hT6PvrqtIfPry_Yo8yKpBkGBxR-jQeBegK3fd8IrAqLnzw-xPURMO6DYSnnMxxozvFw_lZOZ_guVOs5i2ESjMcBx-KAY_1L6p0UBUkdoGH3fth5IHULBmIAR30QGeVcSJkLsEOWyjxOjeK5cBBmcJ1pDY-RM0o7rhnPjbTKRJEWCdzzyGT0EK0VZeGOEc5sYpxNUxtZC1EWzZSIPWIzEFElOWVNdLkQ6xg03KctVOFgTeMfwTbRUdib8STIY1zR-UWMn_xh9inahJUmVSVeeoYaOfzf7hytm08Q9_SiUh249ge9b4AQzm0
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CBTRUS+Statistical+Report%3A+Primary+Brain+and+Other+Central+Nervous+System+Tumors+Diagnosed+in+the+United+States+in+2017-2021&rft.jtitle=Neuro-oncology+%28Charlottesville%2C+Va.%29&rft.au=Price%2C+Mackenzie&rft.au=Ballard%2C+Christine&rft.au=Benedetti%2C+Julia&rft.au=Neff%2C+Corey&rft.date=2024-10-06&rft.issn=1523-5866&rft.eissn=1523-5866&rft.volume=26&rft.issue=Supplement_6&rft.spage=vi1&rft_id=info:doi/10.1093%2Fneuonc%2Fnoae145&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1523-5866&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1523-5866&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1523-5866&client=summon